BILASTINE 20mg. IP

A non-sedating second-generation antihistamine in the treatment of patients with allergic rhinitis and urticaria. (Carter, 2012) Has a quick onset of action than cetirizine, desloratadine, and rupatadine. (Martin K. Church, 2020) Displays a significantly better reduction of itching sensation than desloratadine, rupatadine. (Amalia Leceta, 2021) A well-tolerated drug with significantly less somnolence, and fatigue than cetirizine 10 mg in seasonal allergic rhinitis population. (P Kuna, 2009) A novel safe and effective treatment option for the management of chronic idiopathic urticaria. (T Zuberbier, 2010) An effective treatment for decreasing the symptoms of uremic pruritus. (Amalia Leceta, 2021) An efficacious, safe drug for the treatment of seasonal allergic rhinitis symptoms. (C Bachert, 2009) Induces greater inhibition of the wheal and flare response than desloratadine 5 mg and rupatadine 10 mg. (Rosa Antonijoan, 2017) An efficacious candidate in all nasal symptoms including obstruction and eye symptoms in allergic rhinoconjunctivitis individuals. (Wolthers, 2013) An attractive option for patients with allergic rhinoconjunctivitis or urticaria across age groups from school-age children through to the elderly. (Martin K. Church, 2020)